1998

• Issue #309, December 18, 1998
  1. Complementary Treatments: Dr. Kaiser's New Book
  2. AIDS Treatment News January Publication Schedule
  3. Buyers' Club List, December 1998
  4. AIDS Treatment News Index, 1998

• Issue #308, December 4, 1998
  1. Major Vaccine Project: Largest AIDS Research Grants Ever to Two "Most Promising" Approaches
  2. Disability and Returning to Work: Proposed Change to Let Disabled Keep Benefits
  3. Low-Dose Cyclosporin: Government Trial Recruiting, CD4 Count Over 500
  4. IDSA Conference: Abstracts on the Web
  5. 4th International Congress on Drug Therapy in HIV Infection: Summaries on Web
  6. New Drug Pricing: Progress on World AIDS Day?

• Issue #307, November 20, 1998
  1. GATT and the Gap: How to Save Lives
  2. Testosterone Cream and Gel Available; Prices Vary Greatly
  3. Urgent: Medicaid Rule Changes, Comments Due November 30
  4. Health Insurance: New NAPWA Guide
  5. Flu Season Protection: Information on Web
  6. Retroviruses Conference: Press Must Register by December 31 or Earlier
  7. Medical Marijuana Wins 7 of 7 U.S. Elections
  8. Northern California: HIV Advocacy Conference, December 12-13
  9. Free Newsletter Subscriptions Through Medical Practices, Clinics

• Issue #306, November 6, 1998
  1. T-20 Results Published
  2. U.S. Testosterone Shortage: Call for Information
  3. Abacavir (Ziagen^TM) Approval Recommended
  4. Induction/Maintenance Strategy Failed in U.S., French Trials
  5. Efavirenz (Sustiva^TM) Available through Patient Assistance Program
  6. Amprenavir (Agenerase^TM) Submitted for Approval
  7. National AIDS Treatment Advocates Forum, December 5-8, Philadelphia
  8. Glasgow Conference Reports on Web
  9. Lipodystrophy, Anemia, Resistance, Other Articles at www.healthcg.org/hiv
  10. New TB Guidelines for Persons with HIV
  11. Alitretinoin Gel (Panretin®) FDA Hearing November 16
  12. Record AIDS Funding from Outgoing Congress
  13. Help Wanted, AIDS Treatment Writer, New York
  14. California: Medicaid Expansion Needs Quick Attention after the Election
  15. Youth Consent, Confidentiality for Counselors, San Francisco December 1
  16. California ADAP Update

• Issue #305, October 16, 1998
  1. Retroviruses Conference Scholarship Deadline Nov. 3
  2. AmFAR RFPs: Immune Reconstitution, HIV Vaccines; Grants $75,000 to $150,000, Letter Due November 4
  3. Oakland, California: October 22 Panel on Alternative Treatments
  4. Help Wanted, AIDS Treatment Writer, New York
  5. Nelfinavir (Viracept®) Price Increase 4.6%
  6. 11th National HIV/AIDS Update Conference; Abstract Deadline November 1
  7. Association of Nurses in AIDS Care, November 15-18, San Antonio
  8. San Francisco: Hepatitis C Community Forum, October 20
  9. Cannabis and Cannabidiol: Interview with Robert Gorter, M.D.
  10. California ADAP Alert

• Issue #304, October 2, 1998
  1. Efavirenz (SUSTIVA^TM) Approved
  2. Crixivan® (Indinavir): Three Doses Daily, Not Two, in Most Regimens
  3. Amprenavir (Agenerase^TM) Now Available in Expanded Access
  4. Successful Standard Treatment for Lipid Abnormalities: Experience with 44 Patients
  5. San Francisco: Body Shape Changes and Lipodystrophy -- Community Forum October 19
  6. ICAAC Conference: Daily Summaries Available
  7. Abacavir (Ziagen^TM) Advisory Committee Meeting, November 2
  8. Prison Treatment Programs: Glaxo-Wellcome Awards 19 Grants
  9. Iscador Update: Interview with Robert Gorter, M.D.
  10. United States Conference on AIDS, Dallas, Oct. 29 - Nov. 1
  11. San Francisco: POZ Life Expo, October 16-17

• Issue #303, September 18, 1998
  1. Lipodystrophy Research Coordination Needed
  2. ICAAC Report, September 27, by Telephone Conference
  3. PMPA Trials Recruiting
  4. Improved Viral Load Test: Open Letter on FDA Approval
  5. Acupuncture Research Symposium, Sept. 26-27 at Stanford University
  6. Indigenous Nations AIDS Conference, Prior Lake, Minnesota, September 27-30
  7. Titillationism -- Or, Register Now to Vote!

• Issue #302, September 4, 1998
  1. Post-Exposure Prevention (PEP); What to Do If the Condom Breaks?
  2. New Drug Pricing Consensus Letter, Sign-Ons Requested
  3. Hepatitis C: New Treatment Overview
  4. HIV and Hepatitis Physician Education, San Francisco Sept. 12
  5. IHV 1998 Annual Meeting ("Gallo Lab Meeting"); Program, Many Talks on Web
  6. Fomivirsen Approved for CMV Retinitis: First Antisense Drug
  7. Prison Issues: National Conference, Web Sites
  8. Help Wanted: Executive Director, Project Inform

• Issue #301, August 21, 1998
  1. The CHORUS Database on Patient Clinical Care -- and Interview with Stephen Becker, M.D.
  2. Retroviruses Conference, Jan. 31 - Feb. 4, 1999, Chicago: Abstract Deadline October 1
  3. International Healthcare Resource Allocation Conference, November 15-18, Cancun, Mexico
  4. Herbal Medicine Safety Workshop, National Institutes of Health, Research Triangle Park, September 23 and 24
  5. Medical Marijuana: Strong Support in Oakland
  6. San Francisco: Forum on Body Composition Changes, September 1
  7. San Francisco: Intensive Seminar on Benefits, September 10-11
  8. Help Wanted: Assistant Director, Forum for Collaborative HIV Research
  9. Major Email Security Flaws Discovered: How to Protect Your Data

• Issue #300, August 7, 1998
  1. T-20: New Trial Enrolling, 9 U.S. Cities
  2. New Vaccine+HAART Treatment Trial Enrolling at NIH
  3. Ritonavir Capsule Manufacturing Problems Will Require Switch to Liquid Formulation
  4. Geneva Medical Report Now on Web
  5. Viral Load: Roche Applies for Marketing Approval for UltraSensitive Test
  6. IHV 1998 Annual Meeting (Gallo Lab Meeting) August 23-29 in Baltimore
  7. Geneva Update Town Hall Meeting, August 17, Redwood City, California
  8. San Francisco: Employment-Issues Training for Service Providers, August 19
  9. AIDS Meals and Nutrition Conference, September 10-13, San Francisco
  10. Rural AIDS Conference, Sept. 10-12, Albuquerque
  11. Hepatitis C Conference, August 23-25 in Oakland
  12. Medical Marijuana: Healing Alternatives Begins Distribution
  13. Nutritional Supplements: Call for Information

• Issue #299, July 17, 1998
  1. Efavirenz (Sustiva™) May Equal or Exceed Protease Inhibitor in Initial Antiretroviral Combination
  2. Viral Resistance Overview
  3. Fusion inhibitors, T-20; Chemokine Variants; Tat and Interferon Antibodies: Gallo Describes Three New Treatment Approaches
  4. Geneva Conference: Finding Information on the Web and Elsewhere
  5. AIDS Diarrhea: Phase III Trial Recruiting in Over 30 U.S. Sites
  6. San Francisco: Geneva Conference Review, July 22

• Issue #298, July 10, 1998
  1. HIV-Specific Immune Responses Restored by HIV Immunogen Plus Antiretroviral Suppression
  2. Successful Treatment of "Buffalo Hump" with Growth Hormone
  3. Geneva Conference Treatment Highlights
  4. AIDS Treatment News Internet Directory
  5. Women's Treatment Information and Advocacy: Position at Project Inform
  6. San Francisco, Oakland: Treatment Access and Information Workshop, July 24, July 31, or August 14
  7. Scientific American July Special Report on AIDS

• Issue #297, June 22, 1998
  1. Agouron and Immune Response to Commercialize Remune Immune-Based Treatment
  2. 12th World AIDS Conference, Geneva, June 28 - July 3: How to Participate from Home
  3. Geneva Arrangements (If You Are Going)
  4. Metabolic Complications, Growth Hormone Treatment: New Studies Planned
  5. Ribavirin Approved for Hepatitis C Combination Treatment
  6. Pediatric HIV Treatment: Federal Guidelines Discussed July 22
  7. Congress: How You Can Help
  8. San Francisco: Six-Week Workshop on Returning to Work

• Issue #296, June 5, 1998
  1. New Guide to Living with HIV Infection
  2. Medical Marijuana: Largest Provider Closed, Some Alternatives Available
  3. Medical Marijuana Distribution Summit, Sacramento: Video Available
  4. Efavirenz (Sustiva™, DMP 266) and Saquinavir (Fortovase®) Combination: Pharmacologic Interaction
  5. If You Are Exposed to HIV: Guidelines Published for Postexposure Prevention
  6. Medical Marijuana Study in San Francisco: Pays $1000, 25 Days in Hospital
  7. Acetylcarnitine and Neuropathy: Call for Information
  8. Prison or Discharge Treatment Programs: Funding Available, Proposals Due June 29
  9. Correction: Hepatitis C Trial
  10. Email Experts; Librarians: AIDS Treatment News Seeks Expert Advice
  11. Prospective Case Series in Clinical Trial Design -- Proposal, and NTZ Example

• Issue #295, May 15, 1998
  1. Hepatitis C Important Treatment Advance: Interview with Douglas Dieterich, M.D.
  2. Hepatitis C and HIV: Ribavirin Plus Interferon Study Recruiting
  3. Metabolic Changes: Concerns About Heart, Circulatory Risks
  4. NTZ: Advisory Committee Votes Against Approval
  5. Update on AIDS Wasting and Lipodystrophy: One-Day Seminar in Geneva, June 28
  6. Geneva Conference: Call for Alternative and Traditional Healing Practices Material
  7. AIDS Vaccine: Major Report Available

• Issue #294, May 1, 1998
  1. VIAGRA Warning re "Poppers" and Notice re Protease Inhibitors
  2. Preventing Mother-Infant Transmission Worldwide: What Is Needed? Interview with Joseph Saba, M.D.
  3. HIV Treatment Options
  4. Community Organizing by Email: Needle Exchange Mobilization Example
  5. 15th Annual Candlelight March, May 17
  6. San Francisco: Healing Alternatives Opens Castro Office

• Issue #293, April 17, 1998
  1. T-20 and Trimeris
  2. Adefovir Dipivoxil (PREVEON) Improved Expanded-Access Program
  3. Adefovir Dipivoxil (PREVEON) New Results with Hepatitis B, HIV
  4. HIV/AIDS Nutrition Book for Clinicians
  5. Treatment Conference Call May 2
  6. Geneva Conference Communication Proposals for Minorities Due May 12
  7. New Priority Email Delivery from AIDS Treatment News

• Issue #292, April 3, 1998
  1. AIDS Survival: Major Improvement Documented
  2. Fatigue and HIV: Interview with Lisa Capaldini, M.D. Part II
  3. Nevirapine: One-Year Combination Results Published
  4. Notice on Efavirenz and Pregnancy
  5. AIDSWatch May 3-5 in Washington
  6. Medical Marijuana: Time to Contact Your U.S. Representative
  7. California AIDS Lobby Day, April 20 in Sacramento

• Issue #291, March 20, 1998
  1. Future Directions
  2. Fatigue and HIV: Interview with Lisa Capaldini, M.D.
  3. 1592 (Abacavir, or New Name Ziagen™) More Widely Available March 23
  4. CD4 Increase Despite Protease Inhibitor "Failure" in Swiss Study
  5. March 25 Free Telephone Conference, "Choosing the Right HIV Treatment Strategy"
  6. Women's HIV Treatment Workshop, Oakland, California, March 28
  7. New FDA Commissioner Nomination Soon?

• Issue #290, March 6, 1998
  1. Drug Interactions: Resources for Patients and Professionals
  2. Medical Marijuana Update:
     New Threat to California Access
     Activist Peron Qualifies for Governor's Race
     New Scientist Backgrounder (Available on Web) Reveals Suppressed WHO Analysis
     Comment
  3. Medical Advances with International Impact:
     Maternal Transmission
     TB Prevention
     Easier Sample Preparation
  4. Oral Contraceptive / Nevirapine Interaction Trial, New York and San Francisco
  5. IL-2 Without Antiretroviral Therapy, Trial Near Washington D.C.
  6. FDA Publishes Conflict of Interest Rules for Clinical Trials

• Issue #289, February 20, 1998
  1. Clinical Implications of Virological "Failure":
     Interview with Steven Deeks, M.D., San Francisco General Hospital
  2. Retroviruses Conference Notes
  3. Retroviruses Conference: For More Information
  4. Opportunistic Infections: Major New Report

• Issue #288, February 6, 1998
  1. Organ Transplants: Interview with Jeff Getty, on Ending the Exclusion of People with HIV
  2. HIV/AIDS in Prison Project Threatened: Interview with Judy Greenspan, Director
  3. 5th Retroviruses Conference in Chicago
  4. Adefovir Dipivoxil (PREVEON™): Expanded Access Restrictions Being Eased
  5. NTZ Submitted to FDA for Cryptosporidiosis

• Issue #287, January 23, 1998
  1. Marijuana, Inflammation, and CT-3 (DMH-11C): Cannabis Leads to New Class of Anti-inflammatory Drugs
  2. Medical Marijuana: Federal, State Attacks Against California Cannabis Clubs
  3. Medical Marijuana: The Will Foster Case in Oklahoma
  4. Micronutrients and the HIV Patient, March 23-24 in Boston
  5. Scholarships Available for Geneva Conference: Application Deadline March 8
  6. More Attention to HIV Reporting As GMHC Changes Policy

• Issue #286, January 9, 1998
  1. 1998 Outlook: Treatment, Research, Access
  2. Efavirenz (Sustiva) Expanded Access Now to 400 CD4
  3. San Francisco: Blood Needed for HIV Immunology Studies
  4. Treatment Conferences and Meetings, 1998

1997

• Issue #285, December 19, 1997
  1. New Approaches to HIV Treatment: Interview with Robert Gallo, M.D.
  2. 1592 (Abacavir): Do Not Rechallenge After Hypersensitivity Reaction
  3. Adefovir Dipivoxil (PREVEON™) Expanded Access Begins
  4. San Francisco: Eviction Legislation Protects Some with Major Illness
  5. New York: One-Day Treatment Information Forum, January 17
  6. AIDS Treatment News Index, 1997

• Issue #284, December 5, 1997
  1. Viral Immunology Advances Suggest Treatment Strategies
  2. New Meeting on Immune Surrogate Markers, Baltimore, January 9-11
  3. FDA Approves New Kind of Lymphoma Treatment
  4. Major AIDS Institute Inaugurated in San Francisco
  5. Protease Inhibitor Information: FDA Fact Sheet Available
  6. Protease Inhibitor Failure Trial: Combination 1592, 141W94, and Efavirenz
  7. New AIDS Bookstore on World Wide Web
  8. Revised Federal Antiretroviral Treatment Guidelines
  9. FDA Reform Signed into Law
  10. Press Must Register Now to Cover February Retroviruses Meeting; December 29 Deadline
  11. Correction: FORTOVASE™ Information Number for Patients in Washington D.C. Area
  12. December Deadline for Charitable Giving and Tax Relief

• Issue #283, November 21, 1997
  1. Fortovase^TM Approved: New Saquinavir Formulation
  2. 1592 Access: Larger Program Planned
  3. HIV Resistance Testing: More Questions Than Answers
  4. Drug-Resistant Herpes: Cidofovir Gel in Limbo. Interview with Jay Lalezari, M.D.
  5. Treatment in Developing Countries: New UNAIDS Pilot Program
  6. Geneva Conference Deadlines: Time to Start Planning

• Issue #282, November 7, 1997
  1. HIV Research Overview: Interview with David Ho, M.D.
  2. Expanded Access to Experimental Drugs: Activists Seek More Open Programs
  3. AIDS Dementia: 1592 Now More Available
  4. Qigong Exercise Program Airing in Los Angeles, Orange County; Tape Available
  5. Correction: ICAAC Location
  6. AIDS Service Organizations: Accountability Issue Surfaces in San Francisco

• Issue #281, October 17, 1997
  1. ICAAC Newspaper Headlines Misleading on Protease Inhibitor Failure
  2. ICAAC: Online Summaries Available
  3. Long-Term Strategies: Should Some Patients Wait to Start Protease Inhibitors? -- Interview with Keith Henry, M.D.
  4. Delavirdine Combination and Viral Load
  5. Linezolid, New Antibiotic Studied for MRSA, Available for Compassionate Use
  6. International Conference on AIDS Wasting, Nov. 16-19, Fort Lauderdale, FL
  7. Telephone Conference on Resistance and Cross-Resistance, Nov. 5, 1997
  8. Telephone Conference on HIV Treatment Developments, Oct. 30
  9. Money, Foundations, and the Public Agenda: Investigative Articles Available

• Issue #280, October 3, 1997
  1. Fifty Volunteer for Live-Vaccine Trial
  2. 37th ICAAC Conference, Toronto, Sept. 28 - Oct. 1
  3. Unused Drugs Sought for Donation Abroad
  4. Pregnant Women Eligible for Single-Dose Nevirapine Study
  5. ADAP, Research, and Prevention Funding, and Needle Exchange, Facing Decisions Now in Congress: Your Calls Important
  6. "Poppers"--Annotated Reference List Available
  7. HMOs and Quality Care for HIV -- Interview with Stephen Becker, M.D. (Part 2)

• Issue #279, September 19, 1997
  1. Engineered Virus Targets HIV-Infected Cells: Interview with Garry Nolan, Ph.D.
  2. Efavirenz (SUSTIVA^TM) Expanded Access Begins October 1
  3. Efavirenz (SUSTIVA^TM), Formerly DMP-266) 48-Week Data Announced
  4. T-20: Entirely New Antiretroviral
  5. IDSA '97: Conference Without Activists
  6. IDSA '97: What It Did Right
  7. IDSA '97: Excellent Medical Summaries on Tape

• Issue #278, September 5, 1997
  1. HMOs and Quality Care for HIV -- Interview with Stephen Becker, M.D.
  2. Retroviruses Conferences Deadlines: Community Press and Scholarships November 3; Abstracts October 3; Late-Breaker January 5
  3. DMP 266 Trials Recruiting, Many Cities -- Protease Inhibitor Naive
  4. Adefovir Dipivoxil Trials: CD4 100-500, Protease Inhibitor Naive
  5. Activism: Internet; San Francisco Workshop; Needle Exchange September 17; California Prison HIV Care
  6. Virologic Failure; Managed Care; Treatment Rejectionists; Medical Research: GLMA Achievement Award Address

• Issue #277, August 15, 1997
  1. Protease Inhibitors' Metabolic Side Effects
  2. Taxol Approved for Kaposi's Sarcoma
  3. San Francisco: Changes at Conant Medical Group
  4. IDSA Annual Meeting, September 12-16, San Francisco
  5. 1998 Retroviruses Conference: Deadlines Available Soon
  6. AIDS Treatment News Must Increase Prices
  7. Consensus Letter: Peter Duesberg

• Issue #276, August 1, 1997
  1. 1592 Adult Compassionate-Use Program Announced
  2. Returning to Work: Articles on Social Security Rules
  3. Federal AIDS Policy Issues Today

• Issue #275, July 18, 1997
  1. Health Insurance More Available: Federal Legislation Effective July 1
  2. Pediatric Trial of 141W94, Vertex Protease Inhibitor
  3. Pediatric 1592 Compassionate Use Program Begins
  4. World Wide Web AIDS Medical Information

• Issue #274, July 4, 1997
  1. New Standard of Care for HIV Disease
  2. Major Pediatric Study Stopped Early: Combination Treatment Better
  3. Saquinavir: Major Study Shows Survival Benefit in Treatment- Naive Patients
  4. HIV Resistance International Meeting: Summary on Web; Half- Day Meetings
  5. National Summit Meeting on HIV Resistance, July 17 -- By Telephone
  6. AmFAR Will End Support of CBCT Network, Begin New Clinical Program
  7. Internet Free Speech Upheld
  8. AIDS CARE Newsletter
  9. San Francisco, Healing Alternatives: Help Wanted, Also Directors, Volunteers
  10. California: AIDS Hotline Expands to Cover State, Increases Hours

• Issue #273, June 20, 1997
  1. FDA Explores New Antiretroviral Trial Designs: Interview with David Feigal, M.D.
  2. Protease Inhibitors: FDA Warns Doctors of Diabetes Risk
  3. 1592: Protests on Small Access Program
  4. Help Wanted, Washington D.C.: "Network Correspondent"
  5. San Francisco, Oakland: Treatment Access Workshop, June 27, July 11, July 18

• Issue #272, June 6, 1997
  1. Limited Immune Recovery After Treatment with Antiretrovirals, IL-2
     Interview with Clifford Lane, M.D.
  2. Viral Load in Clinical Trials: FDA Advisory Committee Meeting July 14-15, 1997
  3. Meetings Calendar, June 1997 - 1998

• Issue #271, May 16, 1997
  1. AIDS Treatment News Needs Your Support
  2. Clinical Trials and Viral Load: Statement for FDA Community Meeting May 16
  3. 1592: Small Distribution Programs Begin June, July
  4. Indinavir (Crixivan(R)) Becoming Available at Many Pharmacies
  5. AIDS Internet: Treatment Information Online
  6. AIDS News on the World Wide Web: AEGIS (http://www.aegis.com) and Others
  7. Help Wanted: Project Inform Seeks Hotline Manager
  8. California: ADAP Program Adds Cidofovir, Nevirapine, and Nelfinavir
  9. California: Seventh Annual AIDS Lobby Day, June 2
  10. San Francisco: Lark Lands, Other Experts on Nutrition, Lean Body Mass, & Wasting, June 14

• Issue #270, May 1, 1997
  1. CMV, RS-79070: Community Concern As Major Drug's Development Suspended
  2. CMV Retinitis, Newly Diagnosed: RS-79070 Trial
  3. FDA Community Meeting May 16: Clinical Trials and Viral Load
  4. HIV Vaccines Need to Be Developed: Interview with Sam Avrett, International AIDS Vaccine Initiative
  5. 1st National AIDS Malignancy Conference -- Online Summaries Available from April 28-30 Meeting
  6. Medicaid: AIDS Impact of Proposed Cuts
  7. Medical Marijuana: Questions Raised on San Francisco Raid

• Issue #269, April 18, 1997
  1. Delavirdine (Rescriptor(R)) Approved
  2. Nelfinavir Combination Therapy: Ten-Month Report
  3. PMPA -- First Human Results
  4. Standard Treatments for HIV, Mid 1997
  5. ADAP Drug-Assistance Programs -- Funding Projections for 1998
  6. Medicaid: Vice President Gore Supports Early Treatment
  7. Medical Marijuana Wins Temporary Restraining Order
  8. AIDS/HIV TREATMENT DIRECTORY -- Mailing Address
  9. Meetings Calendar for May 1997

• Issue #268, April 4, 1997
  1. New AmFAR Directory: Best Quick Reference for Mainstream Treatments
  2. NAC, Glutamine, and Alpha Lipoic Acid
  3. Costa Rican PWAs Seek Treatment Access - No Success in Roche Negotiations
  4. Action Alert: Coburn Bill
  5. AIDSWATCH '97: Advocacy in Washington, April 13-15

• Issue #267, March 21, 1997
  1. Ritonavir: New Approval for Children
  2. HIV InSite: University of California AIDS Web Site
  3. Acetylcarnitine: Call for Information
  4. SPV-30: FDA Stops Distribution Over Advertising
  5. It's Time to Approve More Surrogate Markers
  6. AIDS Treatment Activism: Focus on Service

• Issue #266, March 7, 1997
  1. Stanford NAC Study: Glutathione Level Predicts Survival
  2. Glutathione-Depleting Drugs: Petition to the FDA
  3. AIDS Survival: First Drop in Total Deaths in U.S.; Larger Drop in France
  4. Protease Inhibitors: Major Study Stopped When 3-Drug Arm Proves Superior
  5. Help Wanted: GMHC Treatment Education Director
  6. San Francisco: Cattle Grazing, Reservoirs, and Cryptosporidiosis

• Issue #265, February 21, 1997
  1. Fewer AIDS Deaths and Illnesses: New Information
  2. Nelfinavir -- Major Trial Results at Retroviruses Conference
  3. DANGER: Possibly Fatal Interactions Between Ritonavir and "Ecstasy," Some Other Psychoactive Drugs
  4. Free Viral Load Tests Becoming Available for Uninsured Patients
  5. ABT-378: Abbott "Second Generation" Protease Inhibitor
  6. Drug-Related Neuropathy: Low Acetylcarnitine Levels Found
  7. San Francisco: 9th National AIDS Update Conference, March 18-22
  8. New York: Management of the HIV-Infected Patient, March 7-9
  9. New York: ACT UP 10-Year Anniversary: Activist Conference March 22-23, Wall Street Demo March 24
  10. Retroviruses Conference Information: Tape Sales; Email Access
  11. Medical Marijuana: New Nationwide Poll Shows 2-1 Public Support
  12. Medical Marijuana: Followup on THC Toxicology Report

• Issue #264, February 7, 1997
  1. Retroviruses Conference Overview: Consolidating the Advances
  2. Retroviruses Conference: Where to Get Information
  3. Low Vitamin B-12 Blood Levels Associated with Faster Progression to AIDS
  4. Adefovir Dipivoxil: Broad-Spectrum Antiviral Trial, CD4 Count Under 100
  5. Opportunistic Infections: Major Report Available
  6. Acyclovir-Resistant Herpes: Expanded Access Available for Cidofovir Gel
  7. Protease Inhibitor Failures: Call for Information
  8. Non-Approved Liver Treatments: Call for Information
  9. Retroviruses Conference Excludes People with AIDS, Researchers, and Physicians

• Issue #263, January 17, 1997
  1. 1997 Outlook
  2. Nelfinavir: Agouron Announces Expanded Access for Children, a Major New Trial, and Enlarged Expanded Access for Adults
  3. Retroviruses Conference: Where to Find Reporting on the Internet
  4. Medical Marijuana: Unpublished Federal Study Found THC-Treated Rats Lived Longer, Had Less Cancer
  5. Activist Groups and PWA Coalitions, U.S. and Canada

• Issue #262, January 3, 1997
  1. Hundreds Turned Away from National Retroviruses Conference in January
  2. Retroviruses Conference: Daily CME Reports Available on World Wide Web
  3. AIDS Conference Information on the Internet -- How to Present It
  4. San Francisco: Vocational Counseling Workshops

1996

• Issue #261, December 20, 1996
  1. Viral Load Seminars in January and February, Eight U.S. Cities
  2. d4T+AZT -- Unexpected CD4 Drop Seen in Study
  3. 1592: Consensus Letter on Access to New Glaxo Drug
  4. Call for Research on Better Use of Existing Drugs in Advanced Disease
  5. National Conference on Women and HIV -- Late Breaker Deadline March 21
  6. Geneva AIDS Conference Seeks Community Planning Coordinator
  7. Vaccine Report Available
  8. Reminder: AIDS Treatment News Reader Survey
  9. Medical Marijuana: Legal Issues for Physicians and Others
  10. Marijuana and Research
  11. AIDS Treatment News 28-Page Index
  12. AIDS Treatment News Index for 1996

• Issue #260, December 6, 1996
  1. Buyers' Club Crisis -- Challenge for AIDS Communities
  2. Fewer AIDS Deaths: San Francisco Information
  3. FDA Advisory Committee Deadlocks on Delavirdine
  4. Albendazole Free from Buyers' Club
  5. Books: Impure Science
  6. Buyers' Clubs List, December 1996
  7. AIDS Treatment News Reader Survey

• Issue #259, November 15, 1996
  1. Birmingham UK Drug Therapy Conference -- Early Report
  2. Federal Team Developing Treatment Principles for HIV Infection
  3. 1592: Two Studies Recruiting
  4. The New Antiretroviral Arsenal
  5. Medical Marijuana Wins in California and Arizona
  6. FDA Internet Regulation? Public Comment Accepted until December 16
  7. AZT Twice-Daily Tablets Approved; Dosing Concerns
  8. Retroviruses Conference: Press Deadline December 6
  9. Qigong Program on San Francisco KQED TV, Beginning December 7

• Issue #258, November 1, 1996
  1. HCG: New Kind of KS Treatment?
  2. IL-2: Controlled Trial Finds Major CD4 Increases
  3. NTZ for Cryptosporidiosis: Larger Expanded Access; Buyers' Club/FDA Conflict
  4. International Treatment Access and Research, How You Can Help -- Interview with Dr. Peter Piot of UNAIDS
  5. Retroviruses Conference -- Some Scholarships Available
  6. Starting and Changing HIV Treatment: Conference Call Nov. 5, Recording Later
  7. TREATMENT ISSUES Article on New Therapies After Protease Inhibitors
  8. AIDSACT, New Email List for Activists
  9. Hepatitis C: Protease Structure of Virus Published
  10. Bioethics: Major Meetings in San Francisco, November 20-25

• Issue #257, October 18, 1996
  1. Medical Marijuana: The State of the Research
  2. Marijuana and Chocolate
  3. Large Combination Trials with AZT, ddI, ddC: Results Published
  4. Viral Load Access Consensus Statement
  5. Viral Load Seminars for Physicians -- Rescheduled
  6. PhRMA Drops Lawsuit on Government Drug Pricing
  7. Benefits Planning: What You Must Know (Part II)

• Issue #256, October 4, 1996
  1. Grassroots Organizing by Internet: An Example
  2. CKR-5: New Study Confirms Some Do Not Get HIV
  3. Ritonavir and Saquinavir Combination: 12-Week Data at ICAAC
  4. Pharmaceutical Industry Sues to Stop Discount Pricing to Clinics
  5. Congress, Late September 1996: Funding, ADAP, Immigration
  6. 3TC Clinical Benefit: More Data Presented
  7. CMV Information: Print, Online, Phone, Video
  8. Viral Load Seminars for Physicians: Late October Dates in U.S. Cities
  9. Viral Load Overview Available from Treatment Action Group
  10. Washington, October 7: Promoting Treatment and Care in Developing Countries
  11. Benefits: San Francisco Training, November 1

• Issue #255, September 19, 1996
  1. Retroviruses Conference Sets January 22-26 1997 Meeting Dates: Abstract Deadline October 16
  2. Nelfinavir (Viracept™) Expanded Access Announced
  3. ICAAC Conference AIDS Overview -- Available by Toll-Free Phone Call
  4. Washington AIDS Events: Major Demonstrations October 11, 12, and 13
  5. Benefits Planning -- What You Must Know: Interview with Daniel Fortuño, AIDS Benefits Counselors (Part I)

• Issue #254, September 6, 1996
  1. Human Growth Hormone Approved for Wasting
  2. ddI plus d4T
  3. Ritonavir Plus Saquinavir: Two Trials With Different Results
  4. CKR-5 -- Understanding the News
  5. HIV Sensitivity Testing: Organizing for Access
  6. Register to Vote: Time Running Out
  7. AIDS Treatment News Associates (ATNA) Receives Nonprofit Status

• Issue #253, August 23, 1996
  1. Nelfinavir Protease Inhibitor Study Recruiting
  2. Five-Drug or Six-Drug Antiretroviral Therapy -- Conversation with Steven Scheibel, M.D.
  3. 1592 -- New Experimental Antiretroviral
  4. Medical Marijuana: California Update
  5. Calendar of AIDS Research and Treatment Meetings, Late 1996 and Beyond

• Issue #252, August 2, 1996
  1. Editorial: Time to End the Death Trials
  2. 3TC: Combination Trial Stopped Early As Clinical Benefit Shown
  3. ADAP Treatment-Access Emergency -- Interview with William Arnold, ADAP Working Group
  4. Reminder: Free Viral Load Testing From Roche, Only Until August 16
  5. San Francisco Area: "Highlights from Vancouver" at Kaiser Oakland, August 20
  6. DHEA: Modest Viral Load Reduction in Patients
  7. San Francisco Cannabis Buyers' Club Raided Aug. 4

• Issue #251, July 19, 1996
  1. Vancouver in Perspective
  2. New View of Antiretroviral Treatment: Illustrations from "Late Breaker" Abstracts
  3. Expert Panel's New Recommendations for Antiviral Treatment
  4. After Vancouver: Documenting Improved Survival

• Issue #250, July 5, 1996
  1. Cryptosporidiosis: NTZ at Buyers' Club; Customs Holds Second Shipment
  2. NAC: First Controlled Trial, Positive Results
  3. Nevirapine Approved
  4. Vancouver Conference: Each Day Summarized Nightly on World Wide Web
  5. SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web
  6. CMV Retinitis and Treatment: CME Course on World Wide Web
  7. Delavirdine Expanded Access Program Information on World Wide Web
  8. West Hollywood: AIDS and Chinese Medicine Conference, July 25-28
  9. Neuropathy: Nutrient Therapies
  10. World Wide Web: AIDS Treatment News Lists Over 100 Sites

• Issue #249, June 21, 1996
  1. New Optimism on Controlling HIV Infection
  2. Internet Free Speech Wins Court Test
  3. Azithromycin Approved for Once-Weekly MAC Prophylaxis
  4. Nevirapine Recommended for Approval
  5. Free Viral Load Tests: Remember to Dial 1 Before 888
  6. Needlestick Exposure: CDC Recommends Three-Drug Regimen
  7. AIDS and Alternative Medicine: A Journalist's Perspective

• Issue #248, June 7, 1996
  1. Viral Load Approved; Free Test Offered to All in U.S. with HIV
  2. Viral Load: New Recommendations for Clinical Practice
  3. Viral Load: New Proof of Importance for Disease Staging and Prognosis
  4. Op Ed: Viral Load FDA Approval Delays
  5. PMPA: New Information
  6. 3TC: Glaxo Wellcome Broadens Patient Assistance
  7. Prison: California Conference on HIV and Prison Issues, Oakland, June 27
  8. AIDS Treatment News New Index Available
  9. Activist Communications, Activities at Vancouver Conference
  10. "Access for All": Communication Strategy Proposal for International Conference

• Issue #247, May 17, 1996
  1. NIH Scientists Find Cofactor for HIV Entry
  2. World Medicine and Western Medicine: The Missing Dialog -- Interview with Kaiya Montaocean, Co-Director, Center for Natural and Traditional Medicines
  3. Workshop on Traditional Healing and Policy, June 13 Near Washington, D.C.
  4. AIDS Treatment News Back Issues on Web
  5. Best Internet, Computer Sites on AIDS: Request for Information
  6. Computer Communication in Developing Countries: Request for Information
  7. AIDS and Media in Developing Countries: Request for Information
  8. Pharmaceutical Contributions and AIDS Organizations: Request for Input
  9. AIDS Treatment News Policy on Pharmaceutical-Company Revenue

• Issue #246, May 3, 1996
  1. Saquinavir: Combination Shows Survival Benefit; New Formulation Trial Recruiting
  2. Improved HIV Survival Indicates Effect of Therapy
  3. Kaposi's Sarcoma: DaunoXome(R) Approved
  4. Crixivan(R) Price: Behind the Reduction
  5. California: 3TC Now Available through ADAP
  6. Women and HIV: Conference Calls May 14 and May 15, on Treatment Concerns
  7. Alternative Treatments for HIV: Nationwide Survey Seeks Users
  8. Federal Policy: Ryan White, OAR, Testing Newborns
  9. AIDSWatch 1996: National Lobbying Days in Washington, May 19-21
  10. Paris Conference on NAC, Similar Therapeutic Approaches, May 21-23
  11. Vancouver Conference Satellite Meetings, Part II

• Issue #245, April 19, 1996
  1. Crixivan(R) Price Break for Cash Customers: $97 Per Month Less, If You Ask
  2. Protease Inhibitors: Ritonavir and Saquinavir Combination Trial Recruiting
  3. Protease Inhibitors: Background Information
  4. Delavirdine Available on Expanded Access
  5. Sinusitis: Helpful Background, Treatment Article
  6. Chinese Medicine: Qigong Exercise Tape Available
  7. rGP-160 Treatment Vaccine (VaxSyn): Canadian Study Finds No Benefit
  8. FDA Reform in Congress: Interview with Peter Barton Hutt
  9. FDA Reform in Congress: FDA's Concerns
  10. Vancouver Conference: Make Travel Plans Now. Focus, Program, & Satellite Meetings

• Issue #244, April 5, 1996
  1. San Francisco: 3TC Available Now to Residents through ADAP Program
  2. Protease Inhibitors: Patient Education Critical
  3. Indinavir (Crixivan(R)) Access and Distribution
  4. AIDS Research at NIH: Study Panel Issues Major Report
  5. Viral Load: Inconclusive FDA Hearing
  6. AZT, ddI, and ddC Combinations at FDA Advisory Hearing
  7. Cidofovir Recommended for Approval for CMV Retinitis
  8. California: Clinical Trials Computer Service Now Available Statewide
  9. San Francisco Protest Against Meeting Disruptions
  10. California: AB 2812 Would Outlaw Anonymous Testing
  11. AIDS Medications Needed Abroad

• Issue #243, March 15, 1996
  1. Indinavir (Crixivan(R)), Merck Protease Inhibitor, Approved
  2. Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved
  3. Protease Inhibitors at FDA Advisory Hearings
  4. FDA Antiviral Hearings: Community Perspectives
  5. FDA Hearings: For More Information
  6. Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote
  7. Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone
  8. AIDS and Alternative Medicine, Seattle, April 28

• Issue #242, March 1, 1996
  1. Curcumin: Clinical Trial Finds No Antiviral Effect
  2. Protease Inhibitor Approvals -- Will People Be Cut Off Drug? Followup Studies Proposal Needs Support
  3. Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV
  4. Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating HIV
  5. Protease Inhibitors at Retroviruses Conference: Agouron's Results
  6. Retroviruses Conference: Obtaining Copies of Abstracts
  7. DHEA: Threat to Access?

• Issue #241, February, 1996
  1. Merck Protease Inhibitor: More News from Retroviruses Conference
  2. d4T Plus ddI Antiviral Results
  3. Growing Crisis in Paying for Care
  4. AB 9: California Bill Would End County Mandate for Last- Resort Care, Including Communicable Diseases
  5. Press Gag Rules at AIDS Conference

• Issue #240, February 9, 1996
  1. Protease Inhibitors at Retroviruses Conference
  2. Protease Inhibitors in Human Testing: Annotated List
  3. Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS
  4. Agouron Starts Phase III Protease Inhibitor Studies
  5. Vancouver International Conference: Community Booths Deadline Extended
  6. FDA Antiviral Advisory Committee Meetings This Month
  7. Prisoners: Send Address Updates; Contacting Organizations
  8. NMAC Skills Building Conference in South Africa: Facilitators Wanted
  9. Computer Censorship Law, ACLU Test Case, Begin February 8

• Issue #239, January 19, 1996
  1. NTZ: Cryptosporidiosis New Treatment
  2. Viral Load: New Confirmation from Major Delavirdine Studies
  3. Protease Inhibitor Update: Treatment Combination Strategies
  4. Ritonavir: Expanded Access Begins, Warning on Drug Interactions
  5. Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup
  6. Needle Exchange: Experts Deplore Shalala Remarks
  7. Retroviruses Conference Notes
  8. DHEA and AIDS
  9. DHEA Clinical Experience: Interview with Jon Kaiser, M.D.

• Issue #238, January 5, 1996
  1. Getting Your Insurer to Cover New HIV Treatments: A Crash Course
  2. CD8 Cells: Suppressive Factors Discovered
  3. AZT plus 3TC Combination Results Published
  4. Opportunistic Infection Prevention: National Video Symposium January 11
  5. San Francisco: Cryptosporidiosis Water Warning
  6. Computer Censorship Update
  7. Activist Groups, PWA Coalitions, and Buyers' Clubs, U.S. and Canada

1995

• Issue #237, December 22, 1995
  1. Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Info Numbers
  2. Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now
  3. Abbott Protease Inhibitor: Early Results Reported
  4. Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive
  5. Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.
  6. Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease
  7. Human Retroviruses, Immune-Based, and CPCRA Meetings, Wash. D.C. Late Jan.
  8. ACTG Clinical Trial Sites: Seven Cut,Two Added
  9. New York: Protease Inhibitor Forum, January 6
  10. Computer Censorship: Effect on AIDS TREATMENT NEWS

• Issue #236, December 1, 1995
  1. Lamivudine (3TC) Approved for Combination Use with AZT
  2. PMPA in Perspective
  3. DOXIL Approved for KS
  4. New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment
  5. Internet Censorship: Congress Moves Toward Final Decision

• Issue #235, November 17, 1995
  1. Protease Inhibitors: Drug Resistance and Cross Resistance Overview
  2. Grapefruit Juice and Saquinavir
  3. FDA Reform: New Senate Bill

• Issue #234, November 3, 1995
  1. Thalidomide for Wasting Syndrome: Progress Toward Compromise
  2. CMV: Oral Ganciclovir for Prevention
  3. CMV: New Screening Program
  4. Cryptosporidiosis Information Phone/Fax Line
  5. Peptide T: Negative Trial Result

• Issue #233, October 20, 1995
  1. Viral Load: New "Strategy" Trial in 15 U.S. Cities
  2. International Conference, Vancouver 1996: Arrangements and Deadlines
  3. San Francisco Area: Testosterone Replacement Study, Injection vs. Patch

• Issue #232, October 6, 1995
  1. Protease Inhibitors and Prevention of Cross Resistance
  2. AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone
  3. Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV
  4. ICAAC's Small Advances
  5. AIDS Information Obstacles

• Issue #231, September 29, 1995
  1. ICAAC 1995: New Perspectives on Treatment
  2. Major Study Shows AZT Monotherapy Inferior
  3. Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop
  4. Agouron Protease Inhibitor
  5. Saquinavir (Roche Protease Inhibitor) At Higher Doses
  6. Ritonavir, Saquinavir Combination -- and Warning
  7. Symptom-Reduction Trials at FDA Clinical Trials Workshop
  8. Medicaid in Congress: Serious Threat to Health Care

• Issue #230, September 1, 1995
  1. Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.
  2. Hydroxyurea and ddI: French Study Published
  3. Thalidomide: New Expanded Access for Wasting
  4. Health Insurance: Widespread Copayment Abuse

• Issue #229, August 18, 1995
  1. "Confirmatory" Trials: Symptom Reduction As Efficacy Measure
  2. FDA Warning on Raw Oysters
  3. Is NIH AIDS Research in Danger?

• Issue #228, August 4, 1995
  1. New Antiretroviral Strategies: Interview with Marcus Conant, M.D.
  2. 3TC: Now Available Again Up To CD4 of 300
  3. California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients
  4. FDA Reform: Activists' Proposals